Skip to main content
SpringerLink
Log in

Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis

  • Hepatobiliary-Pancreas
  • Published:
European Radiology Aims and scope Submit manuscript

Abstract.

Mangafodipir trisodium (Mn-DPDP, Teslascan) is a well-tolerated liver contrast agent. Although the enhancement characteristics of the cirrhotic liver after Mangafodipir trisodium administration have been studied, at present there is no published data on the impact that cirrhosis might have on the safety and efficacy profiles of this agent. Our objective is to evaluate by means of a retrospective comparison the safety and efficacy of Mangafodipir trisodium in patients with underlying cirrhosis who were examined for suspicion of focal liver lesions. A total of 923 patients received Mangafodipir trisodium (5 µmol/kg) in 11 prospective randomized European clinical trials. Adverse events and discomfort were recorded and graded in all patients. The efficacy analyses were performed on the subsets consisting of 617 patients with independent lesion counts (detection), and on the subset with 399 patients with independent and onsite final lesion diagnosis (characterization). Of the 399 patients, 149 had histologic confirmation. One hundred eighty of 923 patients (19.5%) had cirrhosis. There were no main differences between cirrhotic and non-cirrhotic patients. Adverse events were observed in 64 patients (6.9%), 6.7% in the cirrhotic group and 7.0% in the non-cirrhotic group, a non-significant difference. Adverse events in most patients were mild or moderate. The presence and intensity of the events did not differ between groups. Discomfort was recorded in 79 patients (8.6%), equally distributed in cirrhotic (6.1%) and non-cirrhotic (9.2%) patients. Regarding lesion count, significantly more lesions were found in the post- than in the precontrast images in both the cirrhotic and non-cirrhotic groups (p<0.0001). This increase was not influenced by the presence of liver cirrhosis (p=0.94). Lesion characterization was significantly improved in cirrhotic patients after administration of Mangafodipir trisodium (p=0.002) but not in non-cirrhotic patients (p=0.13). Mangafodipir trisodium is a safe and well-tolerated useful contrast agent in patients with cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–e.

Similar content being viewed by others

References

  1. Elizondo G, Fretz CJ, Stark DD et al. (1991) Preclinical evaluation of Mangafodipir trisodium: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73–78

    Article  CAS  PubMed  Google Scholar 

  2. Wang C, Gordon PB, Hustvedt SO et al. (1997) MR imaging properties and pharmacokinetics of Mangafodipir trisodium in healthy volunteers. Acta Radiol 38:665–676

    Article  CAS  PubMed  Google Scholar 

  3. Hamm B, Vogl TJ, Branding G, Schnell B, Taupitz M, Wolf KJ, Lissner J (1992) Focal liver lesions: MR imaging with Mn-DPDP initial clinical results in 40 patients. Radiology 182:167–174

    Article  CAS  PubMed  Google Scholar 

  4. Murakami T, Baron RL, Federle MP et al. (1996) Cirrhosis of the liver: MR imaging with Mangafodipir trisodium (Mn-DPDP). Radiology 198:567–572

    Article  CAS  PubMed  Google Scholar 

  5. Marti-Bonmati L, Lonjedo E, Poyatos C, Casillas C (1998) MnDDP enhancement characteristics and differentiation between cirrhotic and non-cirrhotic livers. Invest Radiol 33:717–722

    Article  CAS  PubMed  Google Scholar 

  6. Marchal GM, Ni Y, Yu J, Lodemann KP, Baert AL (1993) Mn-DPDP enhanced MRI in experimental bile duct obstruction. J Comput Assist Tomogr 17:290–296

    Article  CAS  PubMed  Google Scholar 

  7. Bernardino ME, Young SW, Lee JK, Weinreb JC (1992) Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. Radiology 183:53–58

    Article  CAS  PubMed  Google Scholar 

  8. Torres CG, Lundby B, Tufte Sterud A, McGill S, Gordon PB, Strand Bjerknes H (1997) Mangafodipir trisodium for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 38:631–637

    CAS  PubMed  Google Scholar 

  9. Bartolozzi C, Donati F, Cioni L, Crocetti L, Lencioni R (2000) Mangafodipir trisodium-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 10:1697–1702

    Article  CAS  PubMed  Google Scholar 

  10. Gresti A (1990) Categorical data analysis. Wiley, New York

  11. Murakami T, Baron RL, Peterson MS, Oliver JH, Davis PL, Confer SR, Federle MP (1996) Hepatocellular carcinoma: MR imaging with Mangafodipir trisodium (Mn-DPDP). Radiology 200:69–77

    Article  CAS  PubMed  Google Scholar 

  12. Federle MP, Chezmar JL, Rubin DL et al. (2000) Safety and efficacy of Mangafodipir trisodium injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials (safety). J Magn Reson Imaging 12:186–197

    Article  CAS  PubMed  Google Scholar 

  13. Marti-Bonmati L, Torregrosa A, Miguel A, Molla E, Dosda R, Arana E (2001) Safety and efficacy of a bolus administration of Mangafodipir trisodium in MR liver studies. Ninth Scientific Meeting ISMRM and 14th Annual meeting ESMRMB

  14. Helmberger TK, Laubenberger J, Rummeny E, Jung G, Sievers K, Dohring W, Meurer K, Reiser MF (2002) MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool. Eur Radiol 12:62–70

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Doctor Peset University Hospital, 46017 , Valencia, Spain

    Luis Martí-Bonmatí

  2. Amersham Health, Oslo, Norway

    Amura F. Fog

  3. Department of Radiology, University Hospital of Antwerp, UZA, Edegem, Belgium

    Bart Op de Beeck

  4. Department of Radiology, King's College Hospital, London, UK

    Pauline Kane

  5. 3S Scandinavian Statistical Services AS, Norway

    Hans Fagertun

Authors
  1. Luis Martí-Bonmatí
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amura F. Fog
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bart Op de Beeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pauline Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans Fagertun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Martí-Bonmatí.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martí-Bonmatí, L., Fog, A.F., de Beeck, B.O. et al. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 13, 1685–1692 (2003). https://doi.org/10.1007/s00330-002-1784-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00330-002-1784-5

Keywords

Search

Navigation